Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis.
Send us all your questions or requests, and our expert team will assist you.
Diagnosis and Staging are the foundational steps that determine the most effective treatment pathway for vulvar cancer patients. At Liv Hospital, our multidisciplinary team combines state‑of‑the‑art technology with international patient services to ensure a precise assessment from the first consultation. Each year, early‑stage detection improves survival rates, with studies showing that up to 70% of vulvar cancers are identified before they spread beyond the primary site. This page guides you through the complete evaluation process, from clinical examination to advanced imaging, and explains how staging informs surgical and systemic therapy decisions. Whether you are a patient traveling from abroad or a referring physician, you will find a clear roadmap of what to expect during your diagnostic journey at our JCI‑accredited facility.
The diagnostic workflow begins with a thorough clinical assessment, followed by targeted tissue sampling and imaging studies. Each step is designed to gather detailed information about tumor size, depth of invasion, and potential spread to surrounding structures.
Accurate diagnosis sets the stage for precise staging, which in turn drives treatment planning. Our experts ensure that each test is selected based on individual patient factors, minimizing unnecessary procedures while maximizing diagnostic yield.
Staging translates the anatomical extent of disease into a standardized language that clinicians worldwide understand. For vulvar cancer, the International Federation of Gynecology and Obstetrics (FIGO) and the American Joint Committee on Cancer (AJCC) TNM system are the most widely used frameworks.
The FIGO stage directly influences surgical margins, the need for lymph‑node evaluation, and whether adjuvant therapy is recommended. Our tumor board reviews each case to confirm the appropriate stage and to tailor the treatment plan accordingly.
Imaging refines the anatomical map created by clinical examination and pathology. Selecting the right modality depends on tumor size, suspected nodal involvement, and the need to detect distant spread.
At Liv Hospital, imaging studies are interpreted by radiologists with expertise in gynecologic oncology, ensuring that the staging information is both accurate and actionable. The integration of imaging findings with pathology results creates a comprehensive picture for the multidisciplinary team.
Beyond confirming malignancy, modern pathology provides insight into tumor biology, which can affect both prognosis and therapeutic options. Molecular markers are increasingly incorporated into the staging conversation.
Sentinel lymph‑node biopsy, performed with a combination of radiocolloid and blue dye, is now the standard for clinically node‑negative patients. This technique reduces morbidity while providing accurate nodal staging. All pathology reports are reviewed in real time during our multidisciplinary meetings to ensure seamless integration into the overall staging assessment.
Once diagnosis and staging are complete, the case is presented to a dedicated tumor board that includes gynecologic oncologists, radiologists, pathologists, radiation oncologists, medical oncologists, and supportive‑care specialists. This collaborative approach guarantees that every aspect of the patient’s disease and personal circumstances is considered.
Based on this comprehensive review, a personalized treatment plan is generated and communicated to the patient in a clear, culturally sensitive manner. Our international patient coordinators ensure that language barriers do not impede understanding of the diagnosis and staging outcomes.
Patients traveling from abroad often face logistical challenges that can delay or complicate the diagnostic process. Liv Hospital’s 360‑degree international patient service eliminates these obstacles, allowing patients to focus on their health.
Our care coordinators work closely with the oncology team to ensure that all diagnostic tests are performed in a streamlined sequence, reducing the overall time from initial consultation to final staging. This patient‑centered approach is especially valuable for those who need to coordinate follow‑up care across time zones.
Liv Hospital combines JCI accreditation, cutting‑edge technology, and a dedicated international patient program to deliver world‑class care for vulvar cancer. Our multidisciplinary experts follow evidence‑based protocols, and our seamless logistics make the diagnosis and staging journey as stress‑free as possible for patients traveling from any country.
Ready to begin your diagnostic journey with confidence? Contact Liv Hospital today to schedule a consultation, and let our international patient team handle every detail—from travel arrangements to personalized staging reports.
Send us all your questions or requests, and our expert team will assist you.
The diagnostic pathway for vulvar cancer starts with a thorough medical history and symptom review, then a focused physical examination of the vulvar region and regional lymph nodes. When indicated, a Pap smear or HPV test is performed. Suspicious lesions are biopsied—incisional, excisional, or punch—providing tissue for histopathology. Imaging modalities such as high‑frequency ultrasound, MRI, CT, or PET‑CT are then used to assess tumor depth, nodal involvement, and distant spread, creating a complete picture for staging.
The FIGO 2024 staging system classifies vulvar cancer from stage IA (tumor ≤2 cm, ≤1 mm depth, no nodal disease) to stage IV (distant metastasis). Stage IB includes larger or deeper tumors without nodal involvement. Stage II indicates extension to adjacent perineal structures, while stage III denotes regional lymph‑node metastasis. Each stage guides surgical margins, the need for lymph‑node assessment, and adjuvant therapy decisions. The tumor board confirms the stage to tailor treatment.
MRI offers superior soft‑tissue contrast, ideal for evaluating depth of invasion and involvement of the urethra or anal sphincter. CT provides a rapid whole‑body overview to assess pelvic and inguinal nodes and distant metastases. PET‑CT detects metabolically active disease, useful when nodal or distant spread is suspected. High‑frequency ultrasound with Doppler allows bedside assessment of superficial nodes and can guide fine‑needle aspiration. The choice depends on tumor size, suspected nodal disease, and need for distant staging.
The hospital’s 360‑degree international patient program handles visa and travel documentation, airport transfers, and local transportation. Professional interpreters are available for every clinical encounter, and patients can choose from hospital‑affiliated hotels or short‑term rentals. Coordinators create personalized schedules to minimize waiting times for biopsies, imaging, and consultations, ensuring a streamlined diagnostic journey from the first appointment to final staging.
Sentinel lymph‑node biopsy (SLNB) is the standard for patients with vulvar cancer who have no palpable inguinal nodes. Using a combination of radiocolloid and blue dye, the sentinel nodes are identified and removed for pathological evaluation. SLNB provides accurate nodal staging with less surgical morbidity compared to full inguinal‑femoral lymph‑node dissection. If the sentinel node is positive, a complete node dissection or adjuvant therapy may be pursued.
BlogCancerNov 03, 2025Vaginal cancer is a rare cancer that’s hard to spot early. About 70% of vaginal cancer cases are foun...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 510 71 24
